Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Y mAbs Therapeutics Inc | YMAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 15.29 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.29 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.60 - 20.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 15.29 | USD |
Y mAbs Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 669.35M | 43.78M | - | 84.82M | -21.43M | -0.49 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Y mAbs Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical YMAB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.93 | 16.39 | 14.7082 | 15.18 | 404,306 | 0.36 | 2.41% |
| 1 Month | 16.48 | 17.49 | 13.34 | 14.99 | 359,701 | -1.19 | -7.22% |
| 3 Months | 12.82 | 20.90 | 11.7001 | 15.42 | 390,763 | 2.47 | 19.27% |
| 6 Months | 4.98 | 20.90 | 4.69 | 12.05 | 329,066 | 10.31 | 207.03% |
| 1 Year | 5.89 | 20.90 | 4.60 | 9.89 | 287,947 | 9.40 | 159.59% |
| 3 Years | 27.97 | 39.8199 | 2.70 | 11.33 | 400,831 | -12.68 | -45.33% |
| 5 Years | 23.42 | 55.36 | 2.70 | 17.49 | 326,542 | -8.13 | -34.71% |
Y mAbs Therapeutics Description
| Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others. |
